Brief Articles
Copyright ©2009 The WJG Press and Baishideng.
World J Gastroenterol. Aug 28, 2009; 15(32): 3999-4004
Published online Aug 28, 2009. doi: 10.3748/wjg.15.3999
Table 1 Characteristics of patients in the diclofenac and control groups1
Diclofenac group (n = 40)Control group (n = 40)P
Variables
Age (yr)260.3 ± 16.159.3 ± 14.50.766
Female sex15 (37.5)22 (55.0)0.116
Bile duct canulation time (min)35.0 (3.0-5.0)5.0 (3.0-10.0)0.601
Operation time (min)315 (15-20)15 (10-25)0.904
Sphincterotomy
Precut10 (25)12 (30)0.617
Pancreatic duct injection19 (47.5)18 (45.0)0.823
Pancreatic duct cannulation, twice or more8 (20.5)6 (15.0)0.556
Post-ERCP pancreatitis3 (7.5)7 (17.5)0.176
Final diagnosis
BD stone23 (57.5)11 (27.5)
SOD3 (7.5)10 (25.0)0.082
Biliopancreatic tumors5 (12.5)9 (22.5)
Others49 (22.5)10 (25.0)
Table 2 Incidence of post-ERCP pacreatitis in different subgroups1
Diclofenac group (n = 40)Control group (n = 40)P
Variables
Age group (yr)
> 602/234/200.300
≤ 601/173/200.420
Sex
Male0/252/180.850
Female3/155/220.092
Pre-cut sphincterotomy
Yes1/104/120.210
No2/303/280.590
Pancreatic duct injection
Yes2/194/180.350
No1/213/220.330
Pancreatic duct cannulation, twice or more2/81/60.730
SOD
Yes2/32/100.150
No1/375/300.0471
Table 3 Serum amylase level (mean ± SE, IU/L) following ERCP in diclofenac and control groups
GroupAmylase 4 hAmylase 8 hAmylase 24 h
Diclofenac223.95 ± 33.45218.39 ± 35.44161.82 ± 31.03
Control283.15 ± 82.74308.34 ± 96231.56 ± 57.73